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Abstract
Mutations in the coding sequence of the X-linked gene MeCP2 (Methyl CpG–binding protein) are present in around 80% of
patients with Rett Syndrome, a common cause of intellectual disability in female and to date without any effective
pharmacological treatment. A relevant, and so far unexplored feature of RTT patients, is a marked reduction in peripheral
circulation. To investigate the relationship between loss of MeCP2 and this clinical aspect, we used the MeCP2 null mouse
model B6.129SF1-MeCP2tm1Jae for functional and pharmacological studies. Functional experiments were performed on
isolated resistance mesenteric vessels, mounted on a pressurized myograph. Vessels from female MeCP2+/2 mice show a
reduced endothelium-dependent relaxation, due to a reduced Nitric Oxide (NO) availability secondary to an increased
Reactive Oxygen Species (ROS) generation. Such functional aspects are associated with an intravascular increase in
superoxide anion production, and a decreased vascular eNOS expression. These alterations are reversed by curcumin
administration (5% (w/w) dietary curcumin for 21 days), which restores endothelial NO availability, decreases intravascular
ROS production and normalizes vascular eNOS gene expression. In conclusion our findings highlight alterations in the
vascular/endothelial system in the absence of a correct function of MeCP2, and uncover related cellular/molecular
mechanisms that are rescued by an anti-oxidant treatment.
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MeCP2 (Methyl CpG-binding protein) is a X-linked epigenetic
transcriptional regulator abundant in pericentric heterochromatin
and widely distributed in a variety of cell types and tissues
including circulatory system and endothelial cells [1,2,3,4].
Mutations in the MECP2 gene are the major documented cause
of Rett Syndrome (RTT), a neurological disorder with a strong
social impact due to its relatively high prevalence in the population
(1/10000 live female births), which makes this disease one of the
most common causes of intellectual disability in females [1,5,6].
Affected children develop normally until 6–18 months of age, after
which time they rapidly regress in purposeful hand use and spoken
language, with the development of gait abnormalities and hand
stereotypies [4]. Furthermore they present severe progressive
anomalies, such as autistic features, seizures, developmental delay,
loss of acquired motor skills and speech [7,8,9,10]. In addition to
the prominent neurological symptoms, children with RTT
frequently present reductions in skeletal growth, hypo-perfusion
in the area of midbrain and upper brainsteam, constipation,
contracted joints, and poor circulation, which lead to bluish tints
to their feet and legs [11,12]. Hydrotherapy and physiotherapy to
the extremities is often used to regain proper circulation and helps
to keep their extremities limber [13].
Different mouse models of Rett Syndrome have been generated
by early embryonic deletion of the gene encoding MeCP2
[14,15,16,17]. All these mouse models present a clear RTT
phenotype that recapitulates what observed in patients[18,19]
[20,21,22]. The MeCP2tm1Jae male mice, herein utilized, exhibit a
significantly reduced body weight, a feature dependent on genetic
background and indicating the presence of genes acting on body
weight and downstream of MeCP2 [14,23]. The MeCP2tm1Jae
male mice present also body tremor and shaking paw by the fifth
week, while heterozygous mutant females develop normally and
are apparently asymptomatic until the age of four months, when
they begin to show pathological symptoms including reduced
activity, ataxic gait, piloerection, stereotyped movements and
heavy breathing [22].
While the neurological phenotype of the Rett syndrome has
been well-characterized in animal models and in humans, the
alterations in the cardiovascular system of MeCP2 deficient mice
have been poorly investigated [24,25] leaving peripheral vascular
functional aspects completely unexplored.
In the last 2 decades, a large body of evidences clearly
documented the critical role played by endothelium in the
modulation of vascular tone and structure, mainly by the
production and release of nitric oxide (NO), which derives by
the activity of the constitutive endothelial enzyme NO synthase
(eNOS) [26,27]. Interestingly, previous work obtained in vitro
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showed a different recruitment of MeCP2 to the eNOS promoter
in human endothelial and vascular smooth muscle cells [28,29].
To date, no effective pharmacological treatment exists for RTT,
neither for the central nervous system nor for peripheral
symptoms. Curcumin (diferuloylmethane) is a natural polyphenol
compound known to interact with multiple targets and used for
centuries to treat a large number of diseases. Micro molar plasma
concentration of curcumin results in anti-oxidant (through
scavenging of free radicals), anti-inflammatory and cardiovascular
properties; lower concentration of curcumin (500 nM) results in a
neurological protective effects increasing the proliferation of
neural stem cells in hippocampus [30,31,32]. It has been shown
that curcumin protects the vascular endothelium, by the produc-
tion of endothelial heme-oxigenase [33,34], while in Alzheimer
disease it counteracts b-amyloid-induced oxidative stress[34] [35].
Some of these observations can be explained by the several
activating and inhibitory actions of the drug on a number of key
signaling pathways, including MAP Kinase, Protein kinase C and
BDNF. Additionally, given its potent activity on histone
deacetylases (more potent that sodium butyrate or valproic acid
[36,37]), curcumin may be considered an epigenetic drug, this
being of potential relevance in the absence of a correct MeCP2-
based chromatin remodelling, like that postulated for RTT
syndrome.
The present study was designed to assess endothelial function in
RTT mice. Specifically we investigated whether the resistance of
mesenteric vessels of symptomatic heterozygous MeCP2 knockout
female and hemizygous male (MeCP2+/2, MeCP2y/2) mice
display an altered endothelium-dependent relaxation vascular
ROS generation, NO availability, and vascular eNOS expression.
The same parameters were analyzed also following curcumin
treatment, to explore the capacity of an- anti-oxidant ‘‘epigenetic’’
drug to rescue the pathological phenotype. Our results demon-
strate that mesenteric resistance arteries from RTT mice are
characterized by endothelial dysfunction caused by a reduced NO
availability secondary to an increased ROS generation, associated
with an intravascular increase in superoxide anion production,
and a decreased vascular eNOS expression. These alterations are
reversed by curcumin administration, which restores endothelial
NO availability, decreases intravascular ROS production and
normalizes vascular eNOS gene expression.
Materials and Methods
Animals
All experiments were carried out in accordance with the
directives of Council of European Communities (86/609/EEC)
and approved by Italian Ministry of Health for the care and use of
laboratories. The animals used for experiments were derived from
heterozygous B6.129SF1-MeCP2tm1Jae knock-out females
(MeCP2+/2) [15]. The animals are maintained through hetero-
zygous females, this because the homozygous unfertile males
present a dramatic phenotype and die within 2 months of age.
Conversely, heterozygous females are fertile, present a certain
degree of variability in the phenotype (due to the X-inactivation
patterns) resembling in this regard more closely the human
pathological condition [38]. Heterozygous females were originally
crossed to C57BL6 for one generation, followed by breeding
among offspring of the same generation with breeder changes and
were maintained on a mixed background. Mixed background
reduced mortality and was necessary to obtain the high numbers
of mice required by extensive analysis. Age-matched female and
male littermates were used in all experiments to control for
possible effects of genetic background unrelated to the MeCP2
mutation [39,40,41]. Mutant and WT mice were reared in
standard conditions. All experiments were performed on animals
with clear symptoms that correspond to six weeks and six months
of age for male (MeCP22/y) and female (MeCP2+/2). respectively
[22]. The age discrepancy was inevitable since male mice are
symptomatics since birth and die within 2 months of age, while
heterozygous females start becoming symptomatic at 5 months of
age, while before are not distinguishable from WT[14].
Curcumin treatment
Six months old MeCP2+/2 mice and age-matched WT female
littermates were distributed into homogeneous experimental
groups (n = 9) taking into account age, weight (Table S1), and
coordination capability (Rotarod test). MeCP2+/2 and WT
received 5% (w/w) dietary curcumin or not for 21 days, as
previously reported [42,43]. Doses of curcumin were chosen
according to previously tested clinical doses well tolerated in
humans [44]. Age-matched MeCP2 +/2 and WT female mice
(n = 5 each) were treated with vehicle for 21 days, as a time-control
study. Rotarod was used to assess the coordination capabilities of
the animals. This was necessary to create symptomatically
matched groups of mice for curcumin or vehicle treatment. We
tested the time spent by the animal on the rotating rod under
continuous acceleration from 4 to 40 rpm. The latency to fall off
the rotating rod was used as an indication of motor coordination
and balance. The task was repeated five times to evaluate the
learning and memory capability.
Vehicle treated mice were not analysed simultaneously to
curcumin treated groups and were added as an assessment of the
natural history of the disease.
During the treatment animals were weighed once a week. After
treatment, animals were sacrificed by cervical dislocation.
HPLC evaluation of plasmatic curcumin
Blood from control and treated animals was isolated by cardiac
puncture and curcumin standard solution was obtained according
to [45]. Briefly, 150 ml of EDTA-stabilized mouse plasma was
mixed with 50 ml of standard curcumin solutions (range 0.1 to
50 mg) of methanol dissolved curcumin (Sigma). Mouse plasma
samples or curcumin standard solution were then measured by
HPLC analysis in a Waters Alliance 2690 HPLC apparatus and
data analysis was performed with Waters Millenium software.
Liquid Chromatographic Conditions: 50 ml sample or standard
solution were injected on to a C18 column 3.96150 mm, 4 mm
particle size, Nova -Pak, Italy), fitted with a security Guard C18
cartridge column (I.D. 4.0 mm63.0mm, Phenomenex srl, Bolo-
gna, Italy). The analysis time was 10 min per sample and the
detection wavelength was 420 nm. The mobile phase was
composed of acetonitrile 5% acetic acid (75:25, v/v) at a flow
rate of 1.0 mL/min. The mobile phase was filtered through a
0.45 mm nylon membrane filter and ultrasonically degassed prior
to use.
Preparation of Small Mesenteric Arteries for Reactivity
Experiments
A second-order branch of the mesenteric arterial tree (<2 mm
in length) was dissected and mounted on 2-glass microcannule in a
pressurized myograph, as described previously [46]. Vessels were
equilibrated for 60 min under constant intraluminal pressure
(45 mm Hg) in warmed (37uC) and bubbled (95% air and 5%
CO2) physiological salt solution, which contained (in mmol/L):
NaCl 120, NaHCO3 25, KCl 4.7, KH2PO4 1.18, MgSO4 1.18,
CaCl2 2.5, EDTA 0.026, and glucose 5.5 (pH 7.4). Vessels were
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considered viable and used if they constricted <70% of their
resting lumen diameter in response to an extraluminal application
of high-potassium (125 mmol/L of KCl) physiological salt solution
containing 100 mmol/L of noradrenaline (NA). In small arteries
from all groups of animals endothelium-dependent relaxation was
assessed by measuring the dilatory response to cumulative
concentrations of acetylcholine (0.001–100 mM, Sigma Chemicals)
in vessels pre-contracted with norepinephrine (10 mM). In
preliminary experiments, we performed a concentration-response
analysis of NA effects (from 1 nM to 100 mM) to establish at which
level this compound was able to elicit similar contractions in
vessels from control and mutant mice. After the titration study, the
dose of 10 mMNA, which induced similar contracting responses in
both groups, was selected (Table 1).
To exclude the possibility that impaired relaxation in response
to acetylcholine resulted from a muscarinic receptor defect, in
additional groups of animals (n = 4 per group), a concentration-
response curve to bradykinin (0.001–1 mM, Sigma Chemicals), an
endothelial agonist acting through a different receptor and signal
transduction pathway,[47] [48] was evaluated. Endothelium-
independent relaxation was assessed by the dilatory response to
sodium nitroprusside (0.01–100 mM, Sigma). To evaluate NO
availability, a curve to acetylcholine was constructed after 30 min
pre-incubation with the NOS inhibitor L-NAME (100 mM,
Sigma). To evaluate the influence of ROS, acetylcholine was
repeated in the presence of the antioxidant ascorbic acid (100 mM,
Sigma, 30-min pre-incubation). Finally, to assess whether ROS
generation can impair NO-mediated endothelium-dependent
relaxation, acetylcholine was infused during simultaneous incuba-
tion with L-NAME and ascorbic acid.
In situ Detection of Superoxide Anion
The in situ production of superoxide anion from 30 mm frozen
mesenteric vessel sections was evaluated by means of the
fluorescent dye dihydroethidium (DHE, Sigma), as previously
described [49]. Three slides per segment were analyzed simulta-
neously after incubation with Krebs solution at 37uC for 30 min.
Krebs-HEPES buffer containing 2 mM DHE was then applied to
each section and evaluated under fluorescence microscopy.
In the presence of superoxide, DHE is oxidized and it
intercalates in cell DNA, thus staining the nucleus with red
fluorescence (excitation at 488 nm, emission 610 nm). A second
acquisition was performed to detect the autofluorescence of elastin.
In the whole artery section, the percentage of arterial wall area
stained with the red signal was normalized to the total area
examined and quantified by means of an image analysis software
(McBiophotonics Image J; National Institutes of Health, Bethesda,
MD).
Determination of Plasma Malondialdehyde Assay
Serum was separated by centrifugation and stored at 280uC
until assay. The colorimetric assessment of malondialdehyde level
was performed according to the technical procedure of the kit
(Cayman Chemical).
RNA extraction and Real Time PCR
Total RNA was isolated from mesenteric vessels with Tripure
(Roche Molecular Biochemicals). First-strand cDNA synthesis was
performed using High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems). Taq-Man quantitative PCR (50uC for
2 min, 95uC for 10 min, followed by 40 cycles of 95uC for 15 s
60uC for 1 min) was used to eNOS mRNA expression. GAPDH
was used as the invariant control. The primers used were all
purchased from Applied Biosystems and reactions were run on a
ABI PRISMH 7700 Sequence Detection System
Immunostaining of eNOS
Small mesenteric arteries were immediately fixed in cold 4%
paraformaldehyde after collection from small bowel loops and
paraffin embedded at 56uC. Eight-micron-thick sections were
serially mounted on glasses and sequentially treated as follows: 1%
hydrogen peroxide in methanol for 30 minutes; microwave
antigen retrieval (600 W in 10 mmol/L of sodium citrate;
pH 6.0); rmal goat serum (1:20; Dakopatts Glostrup, Denmark),
rabbit anti-eNOS polyclonal antibody (sc-654, 1:100 overnight at
4uC, Santa Cruz Biotechnology, Inc., Santa Cruz, CA), biotiny-
lated anti-rabbit immunoglobulins, peroxidase-labeled streptavidin
complex (Vector Laboratories, Burlingame California), 3,3-diami-
nobenzidine tetra-hydrochloride (DAB; Amresco, Solon, OH,
USA), hematoxylin counterstaining. The specificity of eNOS
immunostaining was assessed by preadsorbing the primary
antibody with eNOS blocking peptide (sc-654 P, Santa Cruz
Biotechnology), at 10 times the antibody concentration for 24 h at
4uC. Negative controls were obtained by substituting the primary
antibody with preimmune rabbit serum. Endogenous peroxidases
and avidin-binding activity were assayed by incubating slides with
DAB alone or with peroxidase-labeled streptavidin complex/
DAB, respectively, as previously reported [46]. The slides were
examined under light microscope equipped with the digital
camera DFC480 (Leica, Cambridge, United Kingdom). In the
whole artery section, the percentage of labelled wall area was
quantified by means of an image analysis software (McBiopho-
tonics Image J) and normalized to the total area examined, as
previously reported [50].
Data Analysis
Results are presented as mean6SEM. The statistical signifi-
cance of relaxation responses was assessed taking into consider-
ation time course, treatment and gender by two-way ANOVA.
Response curves comparison within each group were made by
repeated-measures ANOVA or one-way ANOVA followed by a
Student Newman-Keuls test, where appropriate. A value of
P,0.05 was considered statistically significant. Maximal acetyl-
choline- and sodium nitroprusside-induced relaxant responses
(Emax) were calculated as maximal percentage increments of lumen
diameter.
Table 1. Vascular parameters.
Lumen diameter ( mm) VC to NE (10 mM)
Female WT Baseline 219.8630.4 54.861.9
Male WT Baseline 215.5625.7 55.962.5
MeCP2+/2 Baseline 208.6624.5 57.862.4
MeCP2y/2 Baseline 197.2621.6 54.464.1
Female WT Curcumin 221.7627.8 55.764.1
MeCP2+/2 Curcumin 207.4626.8 56.763.8
Female WT Vehicle 226.2635.6 54.165.3
MeCP2+/2 Vehicle 213.6621.7 57.964.6
Table 1. vascular parameter of the mice employed in the curcumin experiment.
Vasoconstriction (VC) norepinephrine (NE).
doi:10.1371/journal.pone.0064863.t001
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Results
Vascular Functional Experiments
In mesenteric vessels from the WT group (n= 9), the relaxation
to acetylcholine was preserved, significantly attenuated by L-
NAME and not affected by ascorbic acid (Figures 1A and 2B).
Vessels from MeCP2+/2 female mice showed a significant (2-way
ANOVA, comparison between curves in panels A and C of
Figure 1, P,0.001) attenuated relaxation to acetylcholine as
compared to WT controls. Indeed, in this group, the inhibitory
effect of L-NAME on relaxation to acetylcholine, although still
evident at the maximal dose, was significantly blunted. In addition,
ascorbic acid potentiated the relaxation to acetylcholine and
restored the inhibitory effect of L-NAME (Figures 1C and 2C).
Similar results were obtained on a group of MeCP2+/2 female
mice bred on the pure 129Sv background (see Figure S1A)
Vessels from MeCP22/y male mice (Figure 1D) were charac-
terized by an exacerbated reduced relaxation to acetylcholine
(with respect to relative WT, Figure 1B) as compared to
MeCP2+/2 female mice (2-way ANOVA, comparison between
curves in panels D and C of Figure 1, P,0.05), which was totally
resistant to L-NAME. Ascorbic acid enhanced only in part the
relaxation to acetylcholine and restored the inhibition by L-
NAME.
Similarly to results obtained with acetylcholine, endothelium-
dependent relaxation to bradykinin was significantly blunted in
vessels from MeCP2+/2 female mice compared with controls
(Emax: 59.661.8% vs 97.161.2%, respectively; P,0.001), and
additionally attenuated in MeCP2y/2 male mice (Emax:
48.261.4%; P,0.01 vs MeCP2+/2).
Relaxation to sodium nitroprusside was similar in female and
male WT and MeCP2+/2 animals (Emax: 97.661.3% and
97.561.1%, respectively), but it was significantly attenuated in
MeCP22/y mice (Emax: 80.961.4%; P,0.01 vs other groups).
Effect of curcumin administration on endothelial function
To evaluate how an antioxidant treatment impacts on the
endothelial phenotype described above symptomatic MeCP2 +/2
and WT female mice were treated with curcumin for 3 weeks.
Mice were fed with food containing curcumin at 5% weight/
weight, a dose proved to result in micromolar concentration of
plasmatic curcumin [43]. Indeed plasma concentration of
curcumin, as assessed by HPLC, was 20.6 mg/ml 61.6 and
19.75 mg/ml 61.4 in WT and MeCP2 +/2 mice respectively.
Food consumption was similar in all groups analyzed: neither
the comparison between curcumin WT versus curcumin RTT
(6.360.7 and 7.360.6 g respectively), nor the comparison
Figure 1. Endothelial relaxation in WT and KO mice. Relaxations to acetylcholine in mesenteric resistance arteries, without (saline) or with L-
NAME, ascorbic acid, or both, in WT female mice (panel A) and WT male mice (panel B), MeCP2+/2 female mice (panel C), or MeCP22/y male mice
(panel D). Results on 9 animals are given as mean6SEM. *P,0.01; {P,0.05; `P,0.001.
doi:10.1371/journal.pone.0064863.g001
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between untreated (referred to as baseline in Figures 2–5) and
curcumin treated RTT animals (8.660.4 and 7.360.6g respec-
tively) revealed any significant difference. The treatment dramat-
ically potentiated (2-way ANOVA, curves in panels 1C and 2B,
P,0.001), but not normalized (comparison Figures 1A and
2B, P,0.05), the relaxation to acetylcholine in mesenteric vessels
from MeCP2+/2 mice, and restored the inhibitory effect of L-
NAME on acetylcholine-induced relaxation (Figures 2B and 2C).
In such arteries, the vascular response to acetylcholine was no
longer affected by ascorbic acid (Figure 2B). Similar results were
obtained on a group of MeCP2+/2 female mice bred on the pure
129Sv background (see Figure S1B). On the contrary, in vessels
from WT mice, curcumin administration did not modify the
relaxation to acetylcholine (Emax: 97.560.9%), the null effect of
ascorbic acid (Emax: 96.860.5%), 96.460.6%), or the inhibitory
effect of L-NAME on acetylcholine (Emax: 58.761.2%; inhibition:
238.160.6%), (2-way ANOVA, comparison between female WT
baseline and female WT curcumin P,0.05)
Relaxations to sodium nitroprusside were not modified by
curcumin administration in MeCP2+/2 and WT (Emax:
97.560.5% and 96.961.1%, respectively).
Time-control study
To evaluate if and how the time employed for curcumin
treatment (3 weeks) impacted on the natural progression of the
disease in terms of endothelial function, separate and not
simultaneously analyzed groups of WT and symptomatically
matched MeCP2+/2 female mice were treated with placebo for 3
weeks. Mice were fed with food prepared as described for the
curcumin added food, but not containing the drug (this group will
be referred to as ‘‘Vehicle’’). In vessels from MeCP2+/2 female
mice, vehicle administration did not significantly modify the
relaxation to acetylcholine, the slight inhibition by L-NAME on
acetylcholine, or the potentiating effect of ascorbic acid, which also
restored the inhibitory effect of L-NAME on acetylcholine
(Figures 2A, 2C). Similarly, in vessels from WT female mice, 3
weeks of vehicle treatment failed to affect the preserved vascular
response to acetylcholine (Emax: 95.860.6%), the null effect of
ascorbic acid (Emax: 96.160.8%), or the inhibitory effect of L-
NAME on acetylcholine (Emax: 57.361.5%; inhibition:
238.560.9%).
Relaxations to sodium nitroprusside were not modified during
the 3 wks period period in MeCP2+/2 and WT groups (Emax:
97.360.8% and 96.961.6%, respectively) with respect to baseline.
Figure 2. Endothelial relaxation in curcumin or vehicle-treated mice. Relaxations to acetylcholine without (saline) or with L-NAME, ascorbic
acid (Asc. acid), or both, in curcumin-treated (panel A) and not simultaneously vehicle-treated (panel B) MeCP2+/2 female mice. *P,0.001 {P,0.001.
Panel C: Bar graph indicates the inhibition by L-NAME on maximal response to acetylcholine (ACh) in vessels from WT and MeCP2+/2 at baseline and
in vessels from MeCP2+/2 mice after curcumin or vehicle administration, without (saline) or with ascorbic (asc) acid. *P,0.001 vs WT, {P,0.05 vs
MeCP2+/2 saline at baseline. Results are given as mean6SEM.
doi:10.1371/journal.pone.0064863.g002
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Effects of curcumin administration on vascular
superoxide generation and malondialdehyde levels
In small arteries from MeCP2+/2 mice, DHE analysis revealed
a dramatic increase in superoxide anion production, as compared
with WT (Figure 3). The enhanced superoxide generation was
significantly attenuated by curcumin but not affected by vehicle
treatment (Figure 3). In vessels from WT, neither curcumin nor
vehicle administration significantly modified the superoxide
detection (Figure 3). In control experiments no autofluorescence
for elastin emerged (data not shown). MeCP2+/2 animals showed
also higher plasma values of malondialdehyde, which were
significantly attenuated, but not normalized, by curcumin and
not significantly modified by vehicle (Figure 4).
Figure 3. Superoxide anion generation: DHE staining and quantification. Representative DHE staining and quantification (bar graph) of the
red signal in mesenteric arteries (magnification X 40) from WT and MeCP2+/2 mice at baseline and after curcumin or vehicle (not simultaneous to
curcumin) administration. Results for 6 experiments are given as mean6SEM. *P,0.01 vs WT, {P,0.05 vs MeCP2+/2 at baseline.
doi:10.1371/journal.pone.0064863.g003
Figure 4. Malondialdehyde (MDA) levels. Plasma levels of MDA of
WT and MeCP2+/2 mice at baseline and after treatment with curcumin
or vehicle (not simultaneous) *P,0.01 vs other groups; {P,0.05 vs WT.
doi:10.1371/journal.pone.0064863.g004
Figure 5. eNOS mRNA expression. Quantitative RT-PCR analysis of
eNOS mRNA expression in mesenteric vessels from WT and MeCP2+/2
mice at baseline and after treatment with curcumin or vehicle (not
simultaneous). eNOS has been normalized to the expression of GAPDH
and data are delta CT-transformations from real time plots 2-way
ANOVA: Genotype effect P,0.05, interaction P,0.01, Bonferroni Post
hoc tests: *P,0.01 vs WT; 1 P,0.05 11P,0.01 vs MeCP2+/2 curcumin
treated.
doi:10.1371/journal.pone.0064863.g005
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Vascular eNOS expressions
eNOS mRNA expression was measured in mesenteric vessels of
Rett animals and WT age-matched littermates. The eNOS
mRNA expression from the mesenteric arterioles was significantly
decreased in MeCP2+/2 mice respect to WT age-matched
littermates, an effect totally reversed by curcumin treatment, but
not modified by vehicle intake. Of note, in the presence of
curcumin, vascular eNOS expression was no longer different from
that of WT animals (Figure 5).
Vascular eNOS immunostaining
In small mesenteric arterioles from WT mice, eNOS was
constitutively expressed within endothelial cells at 1.94% of the
immunoreactive area (SD60.44) (Figure 6A). In contrast, vessels
from MeCP2+/2 animals displayed a significant reduction of
(P,0.001) eNOS immunostaining down to 0.035% of the
immunoreactive area (SD60.01) of the outer vascular smooth
muscle cells, without any appreciable amount at the endothelial
level (Figure 6B).
Discussion
In this study we investigated for the first time the function of the
peripheral microcirculation in a symptomatic MeCP2 knockout
mouse model, and the impact of curcumin administration on its
vascular function. Our findings indicate that these animals are
characterized by an altered endothelium-dependent relaxation
caused by a reduced NO availability due to an increased
intravascular ROS generation. Interestingly, means of curcumin
treatment. we were able to rescue the vasculature dysfunction
The prominent CNS effects of the RTT syndrome have so far
directed a major research effort into the investigation of alterations
taking place in the central nervous system, almost neglecting the
other somatic peripheral symptoms [22], including the circulatory
problems often taking place during the first year of life of RTT
patients [51].
The first finding of the present study concerns the demonstra-
tion of endothelial dysfunction and the underlying mechanisms
responsible for this alteration in RTT male (MeCP22/y) and
female (MeCP2+/2) animal model. Specifically, in the mesenteric
arterioles of the MeCP2+/2 female mice, we observed a dramatic
reduction in the vascular response to acetylcholine, an endothe-
lium-dependent vasodilator, together with a preserved relaxation
to sodium nitroprusside, a direct smooth muscle cell relaxant
compound, indicating the presence of endothelial dysfunction. Of
note, the reduced endothelial function observed in our MeCP2+/2
animal model was obtained with both acetylcholine and brady-
kinin. These 2 agonists act on different receptors and G protein
dependent signal transduction that are respectively sensitive and
insensitive to pertussis toxin [48]. Therefore, our findings indicate
that endothelial dysfunction is not related to a specific defect of the
muscarinic receptor for acetylcholine or to an abnormality of a
single intracellular signal-transduction pathway, but to a more
generalized abnormality of endothelial vasodilator function
present in this animal model.
NO availability and oxidative stress, key parameters of
endothelial functionality, were specifically measured through the
selective NOS inhibitor L-NAME and the ROS scavenger
ascorbic acid, respectively. In MeCP2+/2 mice, the inhibitory
effect exerted by L-NAME on acetylcholine responses was lower
compared with that observed in controls, indicating reduced NO
availability. Ascorbic acid improved the response to acetylcholine
in RTT mice, suggesting that ROS generation contributes to the
endothelial dysfunction observed in this model. When L-NAME
was retested simultaneously with ascorbic acid, its inhibitory effect
on acetylcholine was restored, indicating that in the presence of
ROS scavenging, the activity of the L-arginine-NO pathway was
re-established. Taken together, these findings indicate that ROS
generation represents a major mechanism accounting for endo-
thelial dysfunction in peripheral microcirculation of MeCP2+/2
mice, resulting in NO breakdown. In line with functional data,
MeCP2+/2 mice showed an increased intravascular superoxide
anion generation. The oxidant excess in these animals was also
confirmed by higher plasma values of MDA, a systemic marker of
oxidative stress. Of note, MeCP22/y male animals showed a more
marked endothelial dysfunction compared with MeCP2+/2 female
mice, suggesting that the mosaicism of the female animals is
sufficient to partially maintain the functional activity of the vessels.
Indeed, in the vessels of male mice the NO availability is almost
absent, as evidenced by the acetylcholine-induced relaxation,to-
tally refractory to L-NAME, while ascorbic acid only slightly
restored the inhibitory effect of L-NAME, suggesting a quite
irreversible exhaustion of the L-arginine-NO pathway. In such
context a reduced vascular response to sodium nitroprusside also
emerged, indicating that the detrimental effect of MECP2 deletion
on the vasculature is no longer limited to endothelial function but
it involves the underlying smooth muscle cells. The central nervous
system is particularly sensitive to the adverse effects of oxidative
stress [52] and the presence of systemic oxidative stress in RTT
patients constitutes an intriguing and long debated aspect in Rett
Figure 6. eNOS immunostaining. Representative photomicrograph of immunostaining for eNOS in small mesenteric arteries from WT (A) and
MeCP2+/2mice (B). A strong, specific eNOS staining is detected in endothelium of control vessels (A), while mesenteric arterioles from MeCP2+/2mice
show only a slight eNOS immunostaining corresponding to the outer vascular smooth muscle cells, without any appreciable amount in the
endothelial cell layer (B, arrows). Scale bar 50 mm.
doi:10.1371/journal.pone.0064863.g006
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syndrome pathogenesis [53]. In this perspective, our findings in
rodents are in line with the elevated plasma levels of oxidative
stress, decreased superoxide dismutase activity, and increased
markers of lipid peroxidation [53,54] reported in MeCP2-RTT
patients.
Vessels from curcumin-treated MeCP2+/2 mice showed an
increased relaxation to acetylcholine, which became sensitive to L-
NAME, while ascorbic acid was no longer able to affect the
response to acetylcholine. The demonstration that in the presence
of curcumin L-NAME can inhibit relaxation to acetylcholine, an
effect not exerted under baseline conditions, implies that NO
availability is restored after treatment. It is worth noticing that
after curcumin administration the restored inhibiting effect of L-
NAME on acetylcholine was similar to what observed upon acute
ascorbic acid treatment at baseline. Therefore these findings
suggest that the mechanism responsible for the beneficial effect of
curcumin is probably specific, and related to its antioxidant
properties. This concept is strengthened by curcumin capacity to
attenuate the intravascular superoxide excess, and to reduce the
increased plasma levels of MDA. Of note, the lack of any
significant impact by vehicle intake on endothelial dysfunction in
MeCP2+/2 mice rules out any active role played by the natural
progression of the disease and the observed beneficial effects can
thus be attributed to the pharmacological treatment, at least in the
specific time period investigated.
Our findings extend to the peripheral microcirculation of
MeCP2+/2 mice previous evidence showing the beneficial
antioxidant properties of curcumin on other animal models
affected by oxidative damage [55,56]. It is worth observing that
in the presence of ascorbic acid, both the relaxing effect of
acetylcholine and the inhibitory effect of L-NAME on acetylcho-
line, although significantly improved, did not reach normal values.
Thus, we cannot exclude that other ROS-independent mecha-
nisms may contribute to the MeCP2+/2-related endothelial
dysfunction. Likewise, we recognize that the DHE analysis utilized
in the present study does not allow to exclude that other ROS
different from superoxide may participate in generating intravas-
cular oxidative stress.
Previous reports documented the selective presence of MeCP2
at promoter level of eNOS [28,29], thus raising the hypothesis that
the MECP2 mutation might extend its negative influence to the
regulation of vascular eNOS, the major putative intravascular
source of NO. In line with this concept and with the reduced NO
availability herein reported, isolated mesenteric vessels of MeCP2
deficient mice exhibited decreased eNOS mRNA expression and
marked reduction of eNOS immunostaining, mainly at the level of
endothelial layer, thus providing a mechanistic, although indirect,
insight able to link MECP2 mutation with reduced vascular eNOS
expression in RTT animals. When considering that intravascular
ROS generation is the major mechanism accounting for the NO
breakdown, we can hypothesize that the reduced NO availability
might represent a stimulus for endothelial cells to generate eNOS,
with the consequent inevitable exhaustion of the enzyme. In such
context, the lower eNOS expression may be considered as the
exhausted compensatory attempt by endothelium to generate
NO. Accordingly, chronic antioxidant curcumin might allow the
endothelial cells to restore an adequate availability of the
enzymatic pathway to generate NO. Alternatively, eNOS down-
regulation and ROS excess might represent two simultaneous
alterations which, although generated independently, act syner-
gistically to worse NO availability. This issue needs future
investigations.
It is widely recognized that in physiological conditions, vascular
NO not only causes vasodilation, but also protects the vessel wall
against the development of atherosclerosis [57]. In contrast, the
impaired NO activity and the enhanced activity of vasoconstric-
tors, including ROS, are responsible for impaired vasodilator
capacity. The imbalance of this equilibrium towards oxidative
stress, beyond the altered vasomotricity, also initiates a variety of
active processes, such as inflammation, cell migration and
proliferation, relevant for the endothelial surface and adjacent
wall tissues. For these reasons the altered NO-mediated endothe-
lial function and the increased ROS generation which characterize
the peripheral microcirculation of MeCP2 knockout animals,
might have a causal relationship with the poor circulation present
in the extremities of RTT patients, including cold and cyanotic
legs.
In conclusion, the present study indicates that mesenteric vessels
from MeCP2+/2 female mice are characterized by an altered
endothelium-dependent relaxation caused by a reduced NO
availability due to an increased ROS generation, and by a lower
vascular eNOS expression. These alterations, as well as the
pathological stereotyped movements that characterize the patho-
logical animal, were partially reversed by curcumin administra-
tion. These data revealed that the RTT animal model shares some
of the components of the clinical oxidative and vascular
impairment of RTT patients, who often present circulatory
problems that become increasingly severe in adulthood. It is
proposed that the peripheral vascular system of these animals may
be a source of excessive free radicals contributing to the local and
systemic oxidative stress, and that curcumin based therapy may at
least partly improve RTT symptoms derived from these redox
alterations.
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Figure S1 Endothelial relaxation in pure 129SV
MeCP2+/2 mice and effect of curcumin treatment.
Endothelium-dependent relaxations elicited by Acetylcholine
without (saline) or with L-NAME, ascorbic acid or both, in
mesenteric resistance arteries from MeCP2+/2 female mice at
baseline (A), or after curcumin treatment (B). Each point
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